Literature DB >> 20940191

Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease.

Ola Landgren1, Ruth M Pfeiffer, Sigurdur Y Kristinsson, Magnus Björkholm.   

Abstract

PURPOSE: Autoimmune diseases (AIs) are associated with elevated risk for Hodgkin's lymphoma (HL); however, information on the interplay of AIs and HL on survival is sparse. PATIENTS AND METHODS: We evaluated survival patterns for 7,414 patients with HL in relation to a pre-existing hospital discharge diagnosis of an AI. We also assessed survival patterns in relation to a prior AI diagnosis among 29,240 population-based matched controls.
RESULTS: Among female patients with HL with (v those without) a pre-existing AI, the 5-year and 10-year overall survival was 46.0% (63.3%) and 41.0% (51.9%); for males, the corresponding numbers were 48.5% (59.2%) and 43.6% (51.5%), respectively (P < .001). Among female controls with (v those without) a pre-existing AI, the 5-year and 10-year overall survival was 79.1% (90.2%) and 67.2% (83.3%); for males, the corresponding numbers were 82.5% (90.3%) and 68.6% (81.6%), respectively (P < .001). Female patients with HL with (v those without) a pre-existing AI had a 1.8-fold (range, 1.3- to 2.4-fold) increased relative risk of dying at 5 years of follow-up; for males, the corresponding excess relative risk of dying was 1.7-fold (range, 1.3- to 2.2-fold).
CONCLUSION: Patients with HL have an overall excellent outcome from treatment but also pose some of the most complex challenges of cancer survivorship due to many late effects (eg, second malignancies, thyroid disease, cardiovascular disease, and altered reproductive and sexual function). Our finding that patients with HL with a hospital discharge diagnosis of an AI have a substantially higher risk of dying, emphasizes that underlying chronic diseases, such as AIs, should be high of the list of survivorship concerns for clinicians that treat HL.

Entities:  

Mesh:

Year:  2010        PMID: 20940191      PMCID: PMC3018357          DOI: 10.1200/JCO.2010.29.2243

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  46 in total

1.  Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.

Authors:  T M Dawson; G Starkebaum; B L Wood; R F Willkens; A M Gown
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

2.  Association of cancer with AIDS-related immunosuppression in adults.

Authors:  M Frisch; R J Biggar; E A Engels; J J Goedert
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

Review 3.  Hodgkin lymphoma: the follow-up of long-term survivors.

Authors:  David C Hodgson
Journal:  Hematol Oncol Clin North Am       Date:  2008-04       Impact factor: 3.722

4.  The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study.

Authors:  O Paltiel; T Schmit; B Adler; E A Rachmilevitz; A Polliack; A Cohen; N Haim; M B Shachar; R Epelbaum; M Barchana; R Cohen; D Ben Yehuda
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

5.  Analysis of hereditary component of cancer by use of a familial index by site.

Authors:  B Lindelöf; G Eklund
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

6.  Comorbidity in arthritis.

Authors:  S E Gabriel; C S Crowson; W M O'Fallon
Journal:  J Rheumatol       Date:  1999-11       Impact factor: 4.666

7.  A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden.

Authors:  Y Y Shugart; K Hemminki; P Vaittinen; A Kingman; C Dong
Journal:  Hum Genet       Date:  2000-05       Impact factor: 4.132

8.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.

Authors:  Xavier Mariette; Dominique Cazals-Hatem; Josiane Warszawki; Frédéric Liote; Nathalie Balandraud; Jean Sibilia
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

9.  Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus.

Authors:  Lena Björnådal; Björn Löfström; Li Yin; Ingrid E Lundberg; Anders Ekbom
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

10.  Cancer among children of parents with autoimmune diseases.

Authors:  L Mellemkjaer; F Alexander; J H Olsen
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  4 in total

1.  Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases.

Authors:  Nada Suvajdzic; Predrag Djurdjevic; Milena Todorovic; Maja Perunicic; Roksanda Stojanović; Aleksandra Novkovic; Biljana Mihaljevic
Journal:  Med Oncol       Date:  2011-07-14       Impact factor: 3.064

2.  Does celiac disease influence survival in lymphoproliferative malignancy?

Authors:  Jonas F Ludvigsson; Benjamin Lebwohl; Alberto Rubio-Tapia; Joseph A Murray; Peter H R Green; Anders Ekbom; Fredrik Granath
Journal:  Eur J Epidemiol       Date:  2013-03-05       Impact factor: 8.082

3.  Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy.

Authors:  Jason S Knight; Douglas W Blayney; Emily C Somers
Journal:  Lupus Sci Med       Date:  2014-11-14

4.  History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ebba K Lindqvist; Ola Landgren; Sigrún H Lund; Ingemar Turesson; Malin Hultcrantz; Lynn Goldin; Magnus Björkholm; Sigurdur Y Kristinsson
Journal:  Ann Hematol       Date:  2016-11-02       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.